EUR 3.0
(-0.17%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 58.92 Million EUR | 20.28% |
2022 | 48.99 Million EUR | 1.54% |
2021 | 48.25 Million EUR | 29.76% |
2020 | 37.18 Million EUR | -21.7% |
2019 | 47.49 Million EUR | 43.86% |
2018 | 33.01 Million EUR | 10.81% |
2017 | 29.79 Million EUR | 9.65% |
2016 | 27.16 Million EUR | 28.51% |
2015 | 21.14 Million EUR | 70.65% |
2014 | 12.38 Million EUR | 48.12% |
2013 | 8.36 Million EUR | 60.02% |
2012 | 5.22 Million EUR | -0.0% |
2011 | 5.22 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 32.94 Million EUR | 0.0% |
2023 FY | 58.92 Million EUR | 20.28% |
2023 Q4 | 34.32 Million EUR | 0.0% |
2023 Q2 | 27.92 Million EUR | 0.0% |
2022 Q4 | 23.49 Million EUR | 0.0% |
2022 FY | 48.99 Million EUR | 1.54% |
2022 Q2 | 25.5 Million EUR | 0.0% |
2021 Q4 | 23.37 Million EUR | 0.0% |
2021 FY | 48.25 Million EUR | 29.76% |
2021 Q2 | 24.88 Million EUR | 0.0% |
2020 Q4 | 18.26 Million EUR | 0.0% |
2020 Q2 | 19.03 Million EUR | 0.0% |
2020 FY | 37.18 Million EUR | -21.7% |
2019 Q2 | 21.49 Million EUR | 0.0% |
2019 Q4 | 25.99 Million EUR | 0.0% |
2019 FY | 47.49 Million EUR | 43.86% |
2018 Q4 | 18.5 Million EUR | 0.0% |
2018 FY | 33.01 Million EUR | 10.81% |
2018 Q2 | 14.5 Million EUR | 0.0% |
2017 Q2 | 14.03 Million EUR | 0.0% |
2017 FY | 29.79 Million EUR | 9.65% |
2017 Q4 | 15.75 Million EUR | 0.0% |
2016 FY | 27.16 Million EUR | 28.51% |
2016 Q2 | 13.1 Million EUR | 0.0% |
2016 Q4 | 14.06 Million EUR | 0.0% |
2015 Q4 | 11.59 Million EUR | 0.0% |
2015 Q2 | 9.54 Million EUR | 0.0% |
2015 FY | 21.14 Million EUR | 70.65% |
2014 Q4 | 7.18 Million EUR | 0.0% |
2014 FY | 12.38 Million EUR | 48.12% |
2014 Q2 | 5.2 Million EUR | 0.0% |
2013 Q3 | -2.07 Million EUR | -141.9% |
2013 Q2 | 4.95 Million EUR | 338.68% |
2013 Q1 | -2.07 Million EUR | 0.0% |
2013 FY | 8.36 Million EUR | 60.02% |
2013 Q4 | 4.81 Million EUR | 332.1% |
2012 Q3 | -1.31 Million EUR | 0.0% |
2012 Q1 | -1.31 Million EUR | 0.0% |
2012 Q4 | -2.07 Million EUR | -58.22% |
2012 FY | 5.22 Million EUR | -0.0% |
2012 Q2 | -1.31 Million EUR | 0.0% |
2011 Q3 | -1.64 Million EUR | 0.0% |
2011 Q2 | -1.64 Million EUR | 0.0% |
2011 Q1 | -1.64 Million EUR | 0.0% |
2011 FY | 5.22 Million EUR | 0.0% |
2011 Q4 | -1.31 Million EUR | 20.18% |
2010 Q4 | -1.64 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -1310.75% |
ABIVAX Société Anonyme | 127.37 Million EUR | 53.738% |
Adocia SA | 15.62 Million EUR | -277.036% |
Aelis Farma SA | 18.81 Million EUR | -213.125% |
Biophytis S.A. | 14.33 Million EUR | -311.128% |
Advicenne S.A. | 8.21 Million EUR | -617.31% |
genOway Société anonyme | 16.73 Million EUR | -252.049% |
IntegraGen SA | 5.35 Million EUR | -1000.923% |
Medesis Pharma S.A. | 1.56 Million EUR | -3666.334% |
Neovacs S.A. | 10.34 Million EUR | -469.698% |
NFL Biosciences SA | 4.37 Million EUR | -1247.102% |
Plant Advanced Technologies SA | 2.76 Million EUR | -2031.291% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -3330.047% |
Sensorion SA | 27.05 Million EUR | -117.815% |
Theranexus Société Anonyme | 3 Million EUR | -1860.974% |
TME Pharma N.V. | 5.49 Million EUR | -971.985% |
Valbiotis SA | 9.86 Million EUR | -497.092% |
TheraVet SA | 1.64 Million EUR | -3483.685% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | -189.995% |
DBV Technologies S.A. | 89.4 Million EUR | 34.09% |
Genfit S.A. | 54.8 Million EUR | -7.523% |
GeNeuro SA | 14.35 Million EUR | -310.432% |
Innate Pharma S.A. | 64.57 Million EUR | 8.739% |
Inventiva S.A. | 120.18 Million EUR | 50.97% |
MaaT Pharma SA | 21.59 Million EUR | -172.835% |
MedinCell S.A. | 32.92 Million EUR | -78.99% |
OSE Immunotherapeutics SA | 23.58 Million EUR | -149.807% |
Poxel S.A. | 28.76 Million EUR | -104.857% |
GenSight Biologics S.A. | 32.66 Million EUR | -80.426% |
Transgene SA | 31.23 Million EUR | -88.681% |
Valneva SE | 134.92 Million EUR | 56.326% |